Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gastrointestinal 1

Conditions

Precancerous Conditions 3Breast Neoplasms 3Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Adenomatous Polyposis Coli 2Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pathologic Complete Response 1Pancreatic Intraductal Neoplasms 1Pain 1Melanoma 1Leukemia, Myeloid, Acute 1Inflammation 1Hypertension 1Desmoid Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 146Fluorouracil 137Capecitabine 122Leucovorin 106Irinotecan 85Radiotherapy 67Bevacizumab 64Cetuximab 46Folfox protocol 28Surgical Procedures, Operative 23Radiation 23Drug Therapy 22Panitumumab 19XELOX 18Chemotherapy, Adjuvant 15Neoadjuvant Therapy 14Radiotherapy, Intensity-Modulated 13Chemoradiotherapy 13Magnetic Resonance Spectroscopy 11regorafenib 10Nivolumab 10Floxuridine 10sintilimab 8raltitrexed 8Specimen Handling 8IFL protocol 8Celecoxib 8Biopsy 8trifluridine tipiracil drug combination 7tislelizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Rectal Neoplasms × Sulindac × Clear all
NCT00335504 2017-02-15

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

National Cancer Institute (NCI)

Phase 2 Completed
85 enrolled 10 charts
GastrointestinalOther neoplasm

Colonic Neoplasms, Precancerous Conditions, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡